Evaluation of the protective effect of Cystone against cisplatin-induced nephrotoxicity in cancer patients.

Evaluating the role of cystone, in protecting cancer patients against cisplatin-induced nephrotoxicity, in compare to control group.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016052724625N2

Enrollment

Registered

2016-06-15

Start date

2016-06-04

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nephrotoxicity induced by medications. Nephropathy induced by other drugs, medicaments and biological substances

Interventions

Intervention 1: Patients in first group will receive cisplatin with cystone supplement as 2 capsules, three time a day for 21 days. Intervention 2: Patients in control group receive cisplatine without

Treatment - Drugs

Patients in first group will receive cisplatin with cystone supplement as 2 capsules, three time a day for 21 days.

Patients in control group receive cisplatine without cystone supplement for 21 days.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: Cancer patients assigned to receive cisplatin. Exclusion criteria: Receiving of cisplatin in the past; previous history of renal disease; receiving of any medications that have nephrotoxicity effect.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Serum Creatinine. Timepoint: 22 days after intervention. Method of measurement: Laboratory test.	—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026